Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
INO's Cash to Debt is ranked higher than
85% of the 1281 Companies
in the Global Biotechnology industry.

( Industry Median: 72.05 vs. INO: No Debt )
INO' s 10-Year Cash to Debt Range
Min: 1.17   Max: No Debt
Current: No Debt

Equity to Asset 0.84
INO's Equity to Asset is ranked higher than
87% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. INO: 0.84 )
INO' s 10-Year Equity to Asset Range
Min: 0.49   Max: 0.93
Current: 0.84

0.49
0.93
Interest Coverage No Debt
INO's Interest Coverage is ranked higher than
86% of the 569 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. INO: No Debt )
INO' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 4
Z-Score: 12.54
M-Score: -2.83
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -377.70
INO's Operating margin (%) is ranked higher than
63% of the 1049 Companies
in the Global Biotechnology industry.

( Industry Median: -83.68 vs. INO: -377.70 )
INO' s 10-Year Operating margin (%) Range
Min: -8188.89   Max: -82.67
Current: -377.7

-8188.89
-82.67
Net-margin (%) -345.42
INO's Net-margin (%) is ranked higher than
64% of the 1049 Companies
in the Global Biotechnology industry.

( Industry Median: -80.82 vs. INO: -345.42 )
INO' s 10-Year Net-margin (%) Range
Min: -5759.26   Max: -79.32
Current: -345.42

-5759.26
-79.32
ROE (%) -34.01
INO's ROE (%) is ranked higher than
74% of the 1160 Companies
in the Global Biotechnology industry.

( Industry Median: -33.71 vs. INO: -34.01 )
INO' s 10-Year ROE (%) Range
Min: -152.12   Max: -32.52
Current: -34.01

-152.12
-32.52
ROA (%) -27.85
INO's ROA (%) is ranked higher than
74% of the 1286 Companies
in the Global Biotechnology industry.

( Industry Median: -27.49 vs. INO: -27.85 )
INO' s 10-Year ROA (%) Range
Min: -98.97   Max: -25.77
Current: -27.85

-98.97
-25.77
ROC (Joel Greenblatt) (%) -1003.76
INO's ROC (Joel Greenblatt) (%) is ranked higher than
70% of the 1251 Companies
in the Global Biotechnology industry.

( Industry Median: -373.92 vs. INO: -1003.76 )
INO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -7552.88   Max: -481.97
Current: -1003.76

-7552.88
-481.97
Revenue Growth (3Y)(%) -16.60
INO's Revenue Growth (3Y)(%) is ranked higher than
69% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. INO: -16.60 )
INO' s 10-Year Revenue Growth (3Y)(%) Range
Min: -78   Max: 180.2
Current: -16.6

-78
180.2
EBITDA Growth (3Y)(%) 1.10
INO's EBITDA Growth (3Y)(%) is ranked higher than
80% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -7.20 vs. INO: 1.10 )
INO' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -28.1   Max: 15.7
Current: 1.1

-28.1
15.7
EPS Growth (3Y)(%) 8.30
INO's EPS Growth (3Y)(%) is ranked higher than
85% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. INO: 8.30 )
INO' s 10-Year EPS Growth (3Y)(%) Range
Min: -40.3   Max: 57.1
Current: 8.3

-40.3
57.1
» INO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

INO Guru Trades in Q1 2014

Paul Tudor Jones 31,085 sh (New)
Jean-Marie Eveillard Sold Out
» More
Q2 2014

INO Guru Trades in Q2 2014

Paul Tudor Jones Sold Out
» More
Q3 2014

INO Guru Trades in Q3 2014

Paul Tudor Jones 12,215 sh (New)
» More
Q4 2014

INO Guru Trades in Q4 2014

Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with INO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Inovio Pharmaceuticals Inc

Inovio CEO Invests in 250,000 Shares of Company Stock
The CEO of Inovio Pharmaceuticals Inc (INO), Jong Joseph Kim, purchased 250,000 shares for $2,265,000 on August 12. The average price per share was $9.06. Read more...

Ratios

vs
industry
vs
history
P/B 4.30
INO's P/B is ranked higher than
71% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 6.50 vs. INO: 4.30 )
INO' s 10-Year P/B Range
Min: 0.38   Max: 13.16
Current: 4.3

0.38
13.16
P/S 47.07
INO's P/S is ranked higher than
57% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 30.13 vs. INO: 47.07 )
INO' s 10-Year P/S Range
Min: 1.57   Max: 680
Current: 47.07

1.57
680
EV-to-EBIT -11.62
INO's EV-to-EBIT is ranked higher than
73% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. INO: -11.62 )
INO' s 10-Year EV-to-EBIT Range
Min: -32.5   Max: -0.3
Current: -11.62

-32.5
-0.3
Current Ratio 7.06
INO's Current Ratio is ranked higher than
82% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. INO: 7.06 )
INO' s 10-Year Current Ratio Range
Min: 1.04   Max: 11.87
Current: 7.06

1.04
11.87
Quick Ratio 7.06
INO's Quick Ratio is ranked higher than
83% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: 4.30 vs. INO: 7.06 )
INO' s 10-Year Quick Ratio Range
Min: 1.04   Max: 11.87
Current: 7.06

1.04
11.87
Days Sales Outstanding 97.87
INO's Days Sales Outstanding is ranked higher than
76% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 112.01 vs. INO: 97.87 )
INO' s 10-Year Days Sales Outstanding Range
Min: 6.24   Max: 788.58
Current: 97.87

6.24
788.58

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.70
INO's Price/Net Cash is ranked lower than
52% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 93.33 vs. INO: 6.70 )
INO' s 10-Year Price/Net Cash Range
Min: 2.25   Max: 36.25
Current: 6.7

2.25
36.25
Price/Net Current Asset Value 6.50
INO's Price/Net Current Asset Value is ranked lower than
65% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 39.86 vs. INO: 6.50 )
INO' s 10-Year Price/Net Current Asset Value Range
Min: 2.05   Max: 26.98
Current: 6.5

2.05
26.98
Price/Tangible Book 5.20
INO's Price/Tangible Book is ranked higher than
74% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 10.00 vs. INO: 5.20 )
INO' s 10-Year Price/Tangible Book Range
Min: 1.14   Max: 20.53
Current: 5.2

1.14
20.53
Price/Median PS Value 2.80
INO's Price/Median PS Value is ranked lower than
58% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. INO: 2.80 )
INO' s 10-Year Price/Median PS Value Range
Min: 0.28   Max: 58.82
Current: 2.8

0.28
58.82
Earnings Yield (Greenblatt) -9.50
INO's Earnings Yield (Greenblatt) is ranked higher than
62% of the 1264 Companies
in the Global Biotechnology industry.

( Industry Median: -5.00 vs. INO: -9.50 )
INO' s 10-Year Earnings Yield (Greenblatt) Range
Min: -12.5   Max: 0
Current: -9.5

-12.5
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:GBMB.Germany,
Inovio Biomedical Corporation was originally incorporated on June 29, 1983, under the laws of California as Biotechnologies & Experimental Research, Inc. The entity changed its corporate name to BTX, Inc. on December 10, 1991, and Genetronics, Inc. on February 8, 1994. On April 14, 1994, the board of directors approved a share exchange agreement with Consolidated United Safety Technologies Inc. On September 2, 1997, it listed on the Toronto Stock Exchange as Genetronics Biomedical Ltd, under the laws of British Columbia, Canada, which wholly owned Genetronics, Inc. On June 15, 2001, it completed a change in jurisdiction of incorporation from British Columbia, Canada, to the state of Delaware and became Genetronics Biomedical Corporation, a Delaware corporation. On January 17, 2003, Genetronics voluntarily de-listed from the Toronto Stock Exchange. On March 31, 2005, its corporate name changed from Genetronics Biomedical Corporation to Inovio Biomedical Corporation. On June 1, 2009, it completed the acquisition of VGX Pharmaceuticals, Inc. ('VGX'), a privately-held company, pursuant to the terms of an Amended and Restated Agreement and Plan of Merger dated December 5, 2008, as further amended on March 31, 2009 by and among Inovio, Inovio's wholly-owned subsidiary Inovio Acquisition, LLC and VGX (the 'Merger'). Upon the closing of the Merger, Inovio Acquisition, LLC assumed all of VGX's business, properties and assets and assumed its obligations, changed its name to VGX Pharmaceuticals, LLC, and remains a wholly-owned subsidiary of the Company, utilizing a single, integrated management team with Inovio. On May 14, 2010, the entity changed its corporate name to Inovio Pharmaceuticals, Inc. The Company is engaged in the development of a new generation of vaccines and immune therapies, called synthetic vaccines, focused on cancers and infectious diseases. Its DNA-based SynCon technology is designed to provide universal protection against known as well as new unmatched strains of pathogens such as influenza. These synthetic vaccines, in combination with its proprietary electroporation delivery, have been shown in humans to generate best-in-class immune responses with a favorable safety profile. Its preclinical development and clinical programs include cervical dysplasia/cancer (therapeutic), influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), hepatitis C virus, hepatitis B virus, HIV, and malaria vaccines. The Company faces competition from several development-stage and established enterprises, including major pharmaceutical and biotechnology firms, which are actively engaged in infectious disease and cancer vaccine research and development. Any pharmaceutical products that the Company develops will require regulatory clearances prior to clinical trials and additional regulatory approvals prior to commercialization. The Company's clinical programs include cervical dysplasia (therapeutic), avian influenza (pre
» More Articles for INO

Headlines

Articles On GuruFocus.com
Inovio Pharmaceuticals' CEO Dr. J. Joseph Kim Interviewed by The Life Sciences Report Oct 30 2014 
Inovio CEO Invests in 250,000 Shares of Company Stock Aug 13 2014 
comment on INO May 10 2013 
Weekly CEO Buys Highlight: IBTX, INSM, GERN, INO, EQU Apr 07 2013 
Weekly CFO Buys Highlight: ZBB, INO, LPR, PMC, FGP, PRMW Jun 17 2012 
Weekly CFO Buys Highlight: BWEN, EMC, INO, DCTH, ACCO Jun 11 2012 
Any opinions regarding Apr 12 2010 

More From Other Websites
Nasdaq stocks posting largest percentage increases Mar 27 2015
Can Inovio Help Prevent Cervical Cancer? Mar 20 2015
INOVIO PHARMACEUTICALS, INC. Financials Mar 20 2015
Inovio Pharmaceuticals to Present at Alliance Regenerative Medicine's 2015 Regen Med Investor Day Mar 19 2015
Inovio Pharmaceuticals to Present at Alliance Regenerative Medicine's 2015 Regen Med Investor Day Mar 19 2015
Inovio Pharmaceuticals Appoints Scott M. White, M.D. Vice President, Clinical Development --... Mar 18 2015
Inovio Pharmaceuticals Appoints Scott M. White, M.D. Vice President, Clinical Development --... Mar 18 2015
Company News for March 17, 2015 - Corporate Summary Mar 17 2015
Document for Inovio Pharmaceuticals, Inc. Mar 17 2015
Video-Revolutionizing the Fight Against Cancers and Infectious Diseases for Inovio Pharmaceuticals,... Mar 16 2015
Inovio Pharmaceuticals and Academic Collaborators Receive $16 Million HIV Grant From National... Mar 16 2015
Inovio (INO) Posts Narrower-than-Expected Loss in Q4 - Tale of the Tape Mar 16 2015
Inovio Pharmaceuticals and Academic Collaborators Receive $16 Million HIV Grant From National... Mar 16 2015
INOVIO PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report Mar 16 2015
Q4 2014 Inovio Pharmaceuticals Inc Earnings Release - Before Market Open Mar 16 2015
Inovio Pharmaceuticals Reports 2014 Fourth Quarter and Year End Financial Results Mar 16 2015
Inovio Pharmaceuticals Reports 2014 Fourth Quarter and Year End Financial Results Mar 16 2015
Avian Flu Is Back: Is Inovio Now A Buy? Mar 13 2015
Will Inovio (INO) Disappoint This Earnings Season Again? - Analyst Blog Mar 13 2015
Coverage initiated on Inovio Pharma by H.C. Wainwright Mar 12 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK